Scinai Immunotherapeutics Ltd. (TLV:BVXV)

Scinai Immunotherapeutics Statistics

Total Valuation

TLV:BVXV has a market cap or net worth of ILS 6.11 million. The enterprise value is 25.03 million.

Market Cap	6.11M
Enterprise Value	25.03M

Important Dates

The next estimated earnings date is Monday, May 11, 2026.

Earnings Date	May 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+189.55%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.46
PB Ratio	0.24
P/TBV Ratio	0.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.95
EV / Sales	6.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.30

Financial Position

The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.28.

Current Ratio	1.30
Quick Ratio	1.15
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-0.37
Interest Coverage	-21.01

Financial Efficiency

Return on equity (ROE) is -91.89% and return on invested capital (ROIC) is -42.03%.

Return on Equity (ROE)	-91.89%
Return on Assets (ROA)	-37.60%
Return on Invested Capital (ROIC)	-42.03%
Return on Capital Employed (ROCE)	-75.11%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	134,822
Profits Per Employee	-854,281
Employee Count	31
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +13.07% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+13.07%
50-Day Moving Average	48.03
200-Day Moving Average	63.36
Relative Strength Index (RSI)	53.18
Average Volume (20 Days)	1,402,253

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.49

Income Statement

In the last 12 months, TLV:BVXV had revenue of ILS 4.18 million and -26.48 million in losses. Loss per share was -11.34.

Revenue	4.18M
Gross Profit	-8.45M
Operating Income	-24.04M
Pretax Income	-26.48M
Net Income	-26.48M
EBITDA	-19.51M
EBIT	-24.04M
Loss Per Share	-11.34

Balance Sheet

The company has 5.30 million in cash and 7.23 million in debt, with a net cash position of -1.93 million.

Cash & Cash Equivalents	5.30M
Total Debt	7.23M
Net Cash	-1.93M
Net Cash Per Share	n/a
Equity (Book Value)	25.83M
Book Value Per Share	2.28
Working Capital	1.50M

Cash Flow

In the last 12 months, operating cash flow was -19.23 million and capital expenditures -76,512, giving a free cash flow of -19.30 million.

Operating Cash Flow	-19.23M
Capital Expenditures	-76,512
Depreciation & Amortization	4.33M
Net Borrowing	n/a
Free Cash Flow	-19.30M
FCF Per Share	n/a

Margins

Gross Margin	-202.29%
Operating Margin	-575.29%
Pretax Margin	-633.64%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TLV:BVXV does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-189.55%
Shareholder Yield	-189.55%
Earnings Yield	-433.28%
FCF Yield	-315.82%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:BVXV has an Altman Z-Score of -16.64 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-16.64
Piotroski F-Score	2